Eli Lilly and Company Stock News
$1,183.46
0.13%
NYSE, Sep 25, 04:16 pm EDT.
Closed.
Index
Industry
Eli Lilly and Company Stock News
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes Severe AA can result in extensive hair loss during adolescence, a formative stage of life INDIANAPOLIS, S...
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company's position in the market – including in the burgeoning obesity pill space.
The once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin, Eli Lilly said.
The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-acting insulin injections.
Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
Novo Nordisk wants a bigger presence on Wall Street, and the timing may say more about the drugmaker's challenges than the listing itself. Chief executive Mike Doustdar said Novo could see advantages in replacing its American depositary receipts with shares listed directly in New York.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
